However, these clinical results also demonstrated that the clinical impact of monotherapy with EGFR-directed agents in ESCC, even with EGFR amplification, differs from the dramatic responses seen in EGFR-mutant lung cancer. This evidence concerns the gene EGFR and lung cancer.